Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SORBS2
REST API REST API
Homo sapiens
SORBS2 is differentially expressed in 279 experiments: 155 organism parts: heart, liver, ... (153 more);, 201 disease states: normal, colon carcinoma, ... (199 more);, 79 cell types 419 cell lines 26 compound treatments and 65 other conditions.
Synonyms ARGBP2, KIAA0777
Orthologs Sorbs2 (Rattus norvegicus)   SORBS2 (1 of 2) (Danio rerio)   SORBS2 (Gallus gallus)   Sorbs2 (Mus musculus)   sorbs2a (Danio rerio)   CAP (Drosophila melanogaster)   sorbs2 (Xenopus laevis)   SORBS2 (Bos taurus)   SORBS2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, structural constituent of muscle, cytoplasm, intracellular, biological_process, actin cytoskeleton, nucleus, perinuclear region of cytoplasm, structural constituent of cytoskeleton, cytoskeletal adaptor activity, zinc ion binding, Z disc
InterPro Term Spectrin_alpha_SH3, SH3_domain, SH3_2, Sorb, p67phox
UniProt Accession C9J372, C9J348, C9J3W4, C9J4Z9, C9J4K2, C9IZ89, C9IZT7, C9J620, C9J7Q5, C9J8E3, C9J9D3, C9JBB0, C9JDX2, C9JEA9, C9JBR8, C9JC90, C9JI79, C9JFS9, C9JG84, C9JN77, C9JM25, C9JKV9, O94875, C9JL62, B7Z3X6, C9JWC3, C9JZ60, E9PAS5, E9PAW4
Search EB-eye ENSG00000154556
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-7224, E-GEOD-7540, E-GEOD-3526, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (38 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
A549
2
E-GEOD-3202, E-GEOD-6013
BT-474
2
E-GEOD-5823, E-GEOD-3529
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
DU145
2
E-GEOD-17482, E-GEOD-20089
HCC2157
2
E-MTAB-37, E-MTAB-62
413 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-22373, E-MEXP-2426, E-GEOD-21668, ... (40 experiments)

Factor Value U/D Experiments
embryonic stem cell
1
2
E-MEXP-930, E-MEXP-2426, E-GEOD-26672
adherent cell
1
E-MEXP-551
CD8+ cell
1
E-GEOD-7307
intrathymic T progenitor cell
1
E-GEOD-1460
white blood cell
1
E-GEOD-2006
ciliary muscle
1
E-GEOD-492
73 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, E-MEXP-2280, ... (66 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-GEOD-96, E-GEOD-7307, E-MEXP-2034
colon carcinoma
3
E-MTAB-62, E-MTAB-37, E-MTAB-57
control
3
E-GEOD-21912, E-GEOD-16363, E-GEOD-20602
synovial sarcoma
2
E-GEOD-6481, E-MTAB-37
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
head and neck squamous cell carcinoma
2
E-GEOD-6631, E-GEOD-2379
195 more value(s).


Compound treatment

studied in E-GEOD-5741, E-GEOD-15205, E-GEOD-1417, E-GEOD-3720, E-GEOD-5824, ... (18 experiments)

Factor Value U/D Experiments
lipopolysaccharide
1
E-GEOD-3720
sapphyrin PCI-2051
1
E-GEOD-6400
Cxcl12
1
1
E-GEOD-7307
non-steroidal anti-inflammatory drugs
1
E-GEOD-1919
vanadium pentoxide
1
E-GEOD-5339
unknown
1
E-GEOD-7307
20 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
81 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-MEXP-2359, E-GEOD-6236, E-GEOD-4667, ... (8 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-TABM-147, E-GEOD-21138 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MEXP-1482, E-GEOD-20847, E-MTAB-108, E-GEOD-6431, E-MEXP-563 ... (5 experiments)

Genotype
studied in E-GEOD-1923, E-TABM-1029, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-21612, E-TABM-127, E-GEOD-20504, E-MEXP-1446, E-GEOD-9764, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-GEOD-974, E-MEXP-1956, E-MEXP-2069, E-MEXP-1648, ... (35 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561, E-GEOD-17400

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-548, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19136, E-GEOD-19815, E-GEOD-15799 ... (5 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-6532, E-GEOD-4922

Tumor size
studied in E-GEOD-8167

Processing time: 0.453 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM